ArticlePLoS pathogens2009
B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections.
Article in PLoS pathogens, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 157 citations in OpenAlex.
- Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Trial
- T cells responding to Trypanosoma cruzi detected by membrane TNF-α and CD154 in chagasic patients.Immunity, inflammation and disease · 2018Trial
- The role of IRF5 as an immune regulator.Biochemical Society transactions · 2026Review
- Cytotoxic CD4Parasite immunology · 2026Article
- Review
- Tick-borne coinfections modulate CD8Infection and immunity · 2025Article
- Transcription factor IRF-5 regulates lipid metabolism and mitochondrial function in murine CD8The EMBO journal · 2025Article
- Splenic macrophage functional profile and its role in the immunopathogenesis of canine visceral leishmaniasis.Frontiers in immunology · 2025Article
- T-cell and Soluble Co-inhibitory Receptor Expression in Patients With Visceral Leishmaniasis Are Markers of Treatment Response and Clinical Outcome.Open forum infectious diseases · 2024Article
- Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients.Communications biology · 2024Article
- Within-host bayesian joint modeling of longitudinal and time-to-event data of Leishmania infection.PloS one · 2024Article
- The development and maintenance of immunity against visceral leishmaniasis.Frontiers in immunology · 2024Review
- A molecular signature for IL-10-producing Th1 cells in protozoan parasitic diseases.JCI insight · 2023Article
- Exhausted PD-1Frontiers in immunology · 2022Article
- T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis.Frontiers in immunology · 2022Review
- Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis.The Journal of clinical investigation · 2021Article
- PD-1 Blockade Modulates Functional Activities of Exhausted-Like T Cell in Patients With Cutaneous Leishmaniasis.Frontiers in immunology · 2021Article
- Unraveling the Role of Immune Checkpoints in Leishmaniasis.Frontiers in immunology · 2021Review
- Targeting IL-27 and/or IL-10 in Experimental Murine Visceral Leishmaniasis.The American journal of tropical medicine and hygiene · 2020Article
- IL-33/ST2 axis is involved in disease progression in the spleen during Leishmania donovani infection.Parasites & vectors · 2020Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experimental visceral leishmaniasis (VL) represents an exquisite model to study CD8(+) T cell responses in a context of chronic inflammation and antigen persistence, since it is characterized by chronic infection in the spleen and CD8(+) T cells are required for the development of protective immunity. However, antigen-specific CD8(+) T cell responses in VL have so far not been studied, due to the absence of any defined Leishmania-specific CD8(+) T cell epitopes. In this study, transgenic Leishmania donovani parasites expressing ovalbumin were used to characterize the development, function, and fate of Leishmania-specific CD8(+) T cell responses. Here we show that L. donovani parasites evade CD8(+) T cell responses by limiting their expansion and inducing functional exhaustion and cell death. Dysfunctional CD8(+) T cells could be partially rescued by in vivo B7-H1 blockade, which increased CD8(+) T cell survival but failed to restore cytokine production. Nevertheless, B7-H1 blockade significantly reduced the splenic parasite burden. These findings could be exploited for the design of new strategies for immunotherapeutic interventions against VL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.